PT-141 10 mg — Research Consultation
PT-141 (bremelanotide) is a cyclic seven-amino-acid peptide that acts as a non-selective agonist at the melanocortin MC1, MC3, MC4, and MC5 receptor subtypes. Published research describes CNS-mediated effects through MC4-receptor signalling pathways.
What PT-141 is
PT-141 is a cyclic analogue derived from the α-MSH research lineage. Unlike α-MSH itself, PT-141 is metabolically stable enough to act as a clinically usable research compound, and unlike its predecessor Melanotan II, PT-141 has minimal effect on skin pigmentation at active CNS-research doses. The published pharmacology focuses on MC4-receptor signalling in the central nervous system.
What the published literature covers
Published research describes PT-141 pharmacokinetics, melanocortin-receptor binding affinities at each subtype, and CNS effects mediated through MC4-receptor signalling pathways. Side-effect signals in published research include transient nausea and dose-related blood-pressure changes, both consistent with broader melanocortin-class pharmacology.
Quality verification
Lyophilised PT-141 manufactured under ICH Q7 GMP standards. Independent HPLC verification at a US-based third-party laboratory, ≥98% peak-area purity. COA available through the in-chat consultation.
Common research questions
- Is PT-141 legal in the UAE?
- PT-141 is classified as a research compound in the UAE and is sold through standard wellness-supply channels with VAT compliance applied to every dispatch.
- What dose ranges does the published research describe?
- Published human pharmacology research has used subcutaneous doses of 0.75-1.75 mg in single-dose studies, with active research-relevant effects reported in the lower portion of that range. Higher single doses are associated with a higher incidence of nausea.
- PT-141 vs. Melanotan II — what is the difference?
- Both are α-MSH-derived cyclic analogues. PT-141 was developed downstream of MT-II with the goal of decoupling CNS-research effects from skin-pigmentation effects. PT-141 produces minimal pigmentation at active research doses; MT-II produces marked pigmentation. They are distinct research compounds.
- What is the proposed mechanism?
- PT-141 is a non-selective agonist at melanocortin MC1, MC3, MC4 and MC5 receptors. Published research attributes the CNS-research effects primarily to MC4-receptor activation in hypothalamic and brainstem regions. The mechanism is receptor-pharmacology research, not endocrine-research.
- How is purity verified?
- HPLC peak-area purity (≥98%) at a US-based third-party laboratory. COA available through the chat.
- Shelf life and storage?
- Lyophilised powder is ambient-temperature stable in transit; -20°C long-term storage; refrigerated post-reconstitution per the supplied protocol.
- How fast is delivery in the UAE?
- Same-day delivery within Dubai, next-business-day across the rest of the UAE.
Peer-reviewed references
Related consultations
Further reading
Talk to Nour about your research protocol
Nour reads the peer-reviewed literature and walks you through what each compound is best suited for. English or Arabic, inside the chat.